» Articles » PMID: 21998722

Direct Translocation As Major Cellular Uptake for CADY Self-assembling Peptide-based Nanoparticles

Overview
Journal PLoS One
Date 2011 Oct 15
PMID 21998722
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Cell penetrating peptides constitute a potent approach to overcome the limitations of in vivo siRNA delivery. We recently proposed a peptide-based nanoparticle system, CADY, for efficient delivery of siRNA into numerous cell lines. CADY is a secondary amphipathic peptide that forms stable complexes with siRNA thereby improving both their cellular uptake and biological response. With the aim of understanding the cellular uptake mechanism of CADY:siRNA complexes, we have combined biochemical, confocal and electron microscopy approaches. In the present work, we provide evidence that the major route for CADY:siRNA cellular uptake involves direct translocation through the membrane but not the endosomal pathway. We have demonstrated that CADY:siRNA complexes do not colocalize with most endosomal markers and remain fully active in the presence of inhibitors of the endosomal pathway. Moreover, neither electrostatic interactions with cell surface heparan sulphates nor membrane potential are essential for CADY:siRNA cell entry. In contrast, we have shown that CADY:siRNA complexes clearly induce a transient cell membrane permeabilization, which is rapidly restored by cell membrane fluidity. Therefore, we propose that direct translocation is the major gate for cell entry of CADY:siRNA complexes. Membrane perturbation and uptake are driven mainly by the ability of CADY to interact with phospholipids within the cell membrane, followed by rapid localization of the complex in the cytoplasm, without affecting cell integrity or viability.

Citing Articles

Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly.

Kalmouni M, Oh Y, Alata W, Magzoub M Pharmaceutics. 2024; 16(11).

PMID: 39598566 PMC: 11597747. DOI: 10.3390/pharmaceutics16111443.


Choosing an Optimal Solvent Is Crucial for Obtaining Cell-Penetrating Peptide Nanoparticles with Desired Properties and High Activity in Nucleic Acid Delivery.

Biswas A, Maloverjan M, Padari K, Abroi A, Ratsep M, Warmlander S Pharmaceutics. 2023; 15(2).

PMID: 36839718 PMC: 9963036. DOI: 10.3390/pharmaceutics15020396.


Peptide therapeutics in the management of metastatic cancers.

Bose D, Roy L, Chatterjee S RSC Adv. 2022; 12(33):21353-21373.

PMID: 35975072 PMC: 9345020. DOI: 10.1039/d2ra02062a.


Amphipathic dendritic poly-peptides carrier to deliver antisense oligonucleotides against multi-drug resistant bacteria in vitro and in vivo.

Chen Z, Hu Y, Mao X, Nie D, Zhao H, Hou Z J Nanobiotechnology. 2022; 20(1):180.

PMID: 35366899 PMC: 8977034. DOI: 10.1186/s12951-022-01384-y.


Peptide-Assisted Nucleic Acid Delivery Systems on the Rise.

Tarvirdipour S, Skowicki M, Schoenenberger C, Palivan C Int J Mol Sci. 2021; 22(16).

PMID: 34445799 PMC: 8396486. DOI: 10.3390/ijms22169092.


References
1.
Watkins C, Schmaljohann D, Futaki S, Jones A . Low concentration thresholds of plasma membranes for rapid energy-independent translocation of a cell-penetrating peptide. Biochem J. 2009; 420(2):179-89. DOI: 10.1042/BJ20090042. View

2.
Vercauteren D, Vandenbroucke R, Jones A, Rejman J, Demeester J, De Smedt S . The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther. 2009; 18(3):561-9. PMC: 2839427. DOI: 10.1038/mt.2009.281. View

3.
Via L, Fratti R, McFalone M, Deretic D, Deretic V . Effects of cytokines on mycobacterial phagosome maturation. J Cell Sci. 1998; 111 ( Pt 7):897-905. DOI: 10.1242/jcs.111.7.897. View

4.
Jarver P, Mager I, Langel U . In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol Sci. 2010; 31(11):528-35. DOI: 10.1016/j.tips.2010.07.006. View

5.
Crombez L, Morris M, Dufort S, Aldrian-Herrada G, Nguyen Q, Mc Master G . Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 2009; 37(14):4559-69. PMC: 2724276. DOI: 10.1093/nar/gkp451. View